Vaccine breakthrough infections with omicron sub-lineages induce cross-neutralizing antibodies

Scientists from the Medical University of Vienna, Austria, have recently evaluated the cross-neutralizing potency of serum samples collected from coronavirus disease 2019 (COVID-19) vaccinated and unvaccinated individuals who have been infected with the omicron BA.1 or BA.2 variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The findings reveal that fully vaccinated individuals with omicron breakthrough infections can generate cross-reactive neutralizing antibodies against wild-type SARS-CoV-2, delta variant, and omicron BA.1 and BA.2 variants.

Study: Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization. Image Credit: Fit Ztudio/Shutterstock
Study: Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization. Image Credit: Fit Ztudio/Shutterstock

*Important notice: Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

The study is currently available on the Research Square* preprint server while under consideration at a Nature Portfolio Journal.

Background

The most recently emerged omicron variant of SARS-CoV-2 exhibits a heavily mutated genome compared to other known variants of concern (VOCs). With high numbers of spike mutations, the variant is capable of evading host immunity induced by prior infection or vaccination. There are three distinct sub-lineages of the omicron variant, including BA.1, BA.2, and BA.3. All sub-lineages are characterized by a heavily mutated spike protein.

In individuals without pre-existing immunity, omicron BA.1 infections have been found to induce significantly lower level of neutralizing antibody response against SARS-CoV-2 variants that were circulating before the emergence of omicron. Currently, the BA.2 sub-lineage is gaining global dominance by rapidly replacing the BA.1 sub-lineage. This highlights the possibility of higher transmissibility and immune-evasion ability of the BA.2 sub-lineage than the BA.1 sub-lineage.

In the current study, the scientists have evaluated BA.1, BA.2, and delta-neutralizing ability of serum samples collected from individuals with primary or breakthrough BA.1 or BA.2 infection.

Study design

The scientists collected serum samples from three distinct groups of individuals. The first group included individuals with a history of wild-type SARS-CoV-2, BA.1, or BA.2 infection. The second group included fully vaccinated individuals (three doses of mRNA-based COVID-19 vaccine) with BA.1 or BA.2 breakthrough infection. The third group included individuals with or without prior infection who had received three doses of COVID-19 vaccine.

The neutralizing potency of collected serum samples was tested against wild-type SARS-CoV-2, delta variant, and omicron BA.1 and BA.2 variants.     

Important observations

The serum samples collected three weeks and three months after the third vaccine dose showed potent cross-neutralizing ability against omicron variants (BA.1 and BA.2). However, the neutralizing titer was significantly lower than that against the wild-type virus. The serum samples collected from individuals who had wild-type infection before receiving three vaccine doses also showed cross-neutralizing ability against omicron variants.

The serum samples obtained from wild-type or omicron (BA.1/BA.2)-infected individuals showed significantly lower neutralizing potency against tested variants. Specifically, samples collected three weeks and six months after wild-type infection showed significantly lower neutralizing titers against the omicron variants.

The samples collected from BA.1-infected individuals showed lower neutralizing potency against wild-type virus, delta variant, and BA.2 variant compared to that against the BA.1 variant. In contrast, samples collected after primary BA.2 infection failed to cross-neutralize other tested variants. However, samples collected from individuals with omicron breakthrough infections showed equivalent neutralizing potency against all tested variants (wild-type, delta, and omicron BA.1 and BA.2).

These findings indicate that infections with omicron variants in unvaccinated individuals, especially BA.2 infections, induce variant-specific neutralizing titers. In contrast, omicron breakthrough infections in vaccinated individuals with pre-existing immunity can induce cross-reactive neutralizing antibodies.

Study significance

The study highlights the significance of COVID-19 booster vaccination in inducing cross-neutralizing antibodies. Importantly, the study demonstrates that primary infections with omicron BA.1 and BA.2 induce variant-specific neutralizing antibodies. These two sub-lineages of the omicron variant have similar mutational landscape in the spike protein.

However, mutations present in the N-terminal domain (NTD) of these sub-lineages vary significantly. The antigenic difference observed between the BA.1 and BA.2 sub-lineages could be due to the variation in their NTDs, which contain potent neutralizing epitopes.

*Important notice: Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2022, April 14). Vaccine breakthrough infections with omicron sub-lineages induce cross-neutralizing antibodies. News-Medical. Retrieved on October 06, 2024 from https://www.news-medical.net/news/20220414/Vaccine-breakthrough-infections-with-omicron-sub-lineages-induce-cross-neutralizing-antibodies.aspx.

  • MLA

    Dutta, Sanchari Sinha Dutta. "Vaccine breakthrough infections with omicron sub-lineages induce cross-neutralizing antibodies". News-Medical. 06 October 2024. <https://www.news-medical.net/news/20220414/Vaccine-breakthrough-infections-with-omicron-sub-lineages-induce-cross-neutralizing-antibodies.aspx>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "Vaccine breakthrough infections with omicron sub-lineages induce cross-neutralizing antibodies". News-Medical. https://www.news-medical.net/news/20220414/Vaccine-breakthrough-infections-with-omicron-sub-lineages-induce-cross-neutralizing-antibodies.aspx. (accessed October 06, 2024).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2022. Vaccine breakthrough infections with omicron sub-lineages induce cross-neutralizing antibodies. News-Medical, viewed 06 October 2024, https://www.news-medical.net/news/20220414/Vaccine-breakthrough-infections-with-omicron-sub-lineages-induce-cross-neutralizing-antibodies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 vaccine uptake higher in people with mental illness but drops for those not on medication